Psoriasis: An opportunity to identify cardiovascular risk

British Journal of Dermatology

Volumn 160, Issue 1, 2009, Pages 1-7

  Federman, D G ^a   Shelling, M ^b   Prodanovich, S ^b   Gunderson, C G ^a   Kirsner, R S ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Hypertension; Myocardial infarction; Psoriasis

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINE; NICOTINE PATCH; NICOTINIC ACID; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; VARENICLINE;

ANAL LEAKAGE; ANUS DISEASE; ARTERY DISEASE; ATHEROSCLEROSIS; BARIATRIC SURGERY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DISEASE ASSOCIATION; DRUG MECHANISM; DYSLIPIDEMIA; FLATULENCE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE TOLERANCE TEST; GREASY STOOL; HEALTH PRACTITIONER; HEART INFARCTION; HEMORRHAGIC STROKE; HUMAN; HYPERTENSION; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MORTALITY; NICOTINE REPLACEMENT THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PULSE RATE; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION; STEATORRHEA; STROKE; TOBACCO DEPENDENCE; XEROSTOMIA;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; FEMALE; HUMANS; INTERLEUKIN-2; MALE; OBESITY; PSORIASIS; RISK FACTORS; SMOKING; TH1 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 57649220627     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08874.x     Document Type: Review

References (83)

1. National Psoriasis Foundation. Psoriasis Statistics. Available at: http://www.psoriasis.org/about/stats (last accessed 4 June 2008).
2. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 7.
3. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 137 : 280 4.
4. Rapp SR, Exum ML, Reboussin DM et al. The physical, psychological, and social impact of psoriasis. J Health Psychol 1997 2 : 525 37.
5. Schon MP, Boehncke W-H. Psoriasis. N Engl J Med 2005 352 : 1899 912.
6. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 : 1735 41.
7. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis. Results from a population-based study. Arch Dermatol 2007 143 : 1493 9.
8. Lebwohl M. Psoriasis. Lancet 2003 361 : 1197 204.
9. Krueger G, Ellis CN. Psoriasis - recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005 53 (1 Suppl. 1 S94 100.
10. Lee MG, Cooper AJ. Immunopathogenesis of psoriasis. Aust J Dermatol 2006 47 : 151 9.
11. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005 64 (Suppl. 2 ii30 6.
12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 : 1685 95.
13. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007 57 : 1059 68.
14. Ranjbaran H, Sokol SI, Gallo A et al. An inflammatory pathway of IFN-gamma production in coronary atherosclerosis. J Immunol 2007 178 : 592 604.
15. Wolfe R, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003 30 : 36 40.
16. Rhew EY, Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus - role of inflammatory mechanisms. Autoimmun Rev 2006 5 : 101 5.
17. Shapiro J, Cohen AD, David M et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007 56 : 629 34.
18. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2006 20 : 52 5.
19. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995 32 : 982 6.
20. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006 54 : 614 21.
21. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001 303 : 33 9.
22. Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006 298 : 321 8.
23. Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006 55 : 829 35.
24. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007 120 : 953 9.
25. Fortes C, Mastroeni S, Leffondre K et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005 141 : 1580 4.
26. Huerta C, Rivero E, Garcia Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007 143 : 1559 65.
27. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006 295 : 1549 55.
28. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends 1960-1994. Int J Obes Relat Metab Disord 1998 22 : 39 47.
29. Adams KF, Schatzkin A, Harris TB et al. Overweight, obesity, and mortality in a large cohort of persons 50-71 years old. N Engl J Med 2006 355 : 763 78.
30. Haslam DW, James WPT. Obesity. Lancet 2005 366 : 1197 209.
31. Li Z, Bowerman S, Heber D. Health ramifications of the obesity epidemic. Surg Clin North Am 2005 85 : 681 701.
32. Herron MD, Hinckley M, Hoffman MS et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005 141 : 1527 34.
33. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002 346 : 591 602.
34. Consensus Panel. Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992 55 (Suppl. 2 615S 19S.
35. Sjostrom J, Narbro K, Sjostrom CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007 357 : 741 52.
36. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003 289 : 2560 72.
37. Lewington S, Clark R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002 360 : 1903 13.
38. Neal B, MacMahon S, Chapman S. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs. Lancet 2000 356 : 1955 64.
39. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000 1 : 159 65.
40. Gold MH, Holy AK, Roenigk HH Jr. Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol 1988 19 : 837 41.
41. Yilmaz MB, Turhan H, Akin Y et al. Beta-blocker-induced psoriasis: a rare side effect - a case report. Angiology 2002 53 : 737 9.
42. Dika E, Bardazzi F, Balestri R, Maibach HI. Environmental factors and psoriasis. Curr Probl Dermatol 2007 35 : 118 35.
43. Cohen AD, Bonneh DY, Reuveni H et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol 2005 85 : 299 303.
44. Wolf R, Dorfman B, Krakowski A. Psoriasiform eruption induced by captopril and chlorthalidone. Cutis 1987 40 : 162 4.
45. Antonov D, Grozdev I, Pehlivanov G, Tsankov N. Psoriatic erythroderma associated with enalapril. Skinmed 2006 5 : 90 2.
46. Kawamura A, Ochiai T. Candesartan cilextil induced pustular psoriasis. Eur J Dermatol 2003 13 : 406 7.
47. Marquart-Elbaz C, Grosshans E, Alt M, Lipsker D. Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol 2002 147 : 617 18.
48. Diabetes Control and Complications Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993 329 : 978 86.
49. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993 329 : 304 9.
50. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS33). Lancet 1998 352 : 837 53.
51. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS34). Lancet 1998 352 : 854 65.
52. Diabetes Control and Complications Group/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 53.
53. Bastien A. The ACCORD trial: a multidisciplinary approach to control cardiovascular risk in type 2 diabetes mellitus. Pract Diabetol 2004 23 : 6 11.
54. Hagforsen E, Michaelsson K, Lundgren E et al. Women with palmopustular psoriasis have disturbed calcium homeostasis and a high prevalence of diabetes mellitus and psychiatric disorders: a case-control study. Acta Derm Venereol 2005 85 : 225 32.
55. Binazzi M, Calandra P, Lisi P. Statistical association between psoriasis and diabetes: further results. Arch Dermatol Res 1975 254 : 43 8.
56. Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003 26 : 3160 7.
57. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 72.
58. Centers for Disease Contol and Prevention (CDC). Cigarette smoking among adults - United States, 1999. MMWR Morb Mortal Wkly Rep 2001 50 : 869 73.
59. Centers for Disease Contol and Prevention (CDC). Tobacco use - United States, 1990-1999. MMWR Morb Mortal Wkly Rep 1999 48 : 986 93.
60. Department of Health and Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. DHHS Publication no. (CDC) 90-8416. Washington, DC : Government Printing Office, 1990.
61. Fiore MC, Bailey WC, Cohen SJ et al. Treating Tobacco Use and Dependence. Rockville, MD : Department of Health and Human Services, Public Health Service, 2000.
62. Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med 2002 346 : 506 12.
63. Glover ED, Rath JM. Varenicline: progress in smoking cessation treatment. Expert Opin Pharmacother 2007 8 : 1757 67.
64. Nides M, Oncken C, Gonzales D et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7 week, randomized, placebo- and buproprion-controlled trial with 1-year follow-up. Arch Intern Med 2006 166 : 1561 8.
65. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007 164 : 1269 70.
66. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007 164 : 1269.
67. Hughes JR, Goldstein MG, Hurt RD, Schiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999 281 : 72 6.
68. Chen Z, Peto R, Collins R et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991 303 : 276 82.
69. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 356 : 1267 78.
70. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
71. Grundy SM, Cleeman JI, Merz NB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Panel III Guidelines. Circulation 2004 110 : 227 39.
72. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of coronary heart disease in apparently healthy men. N Engl J Med 1997 336 : 973 9.
73. Stampfer MJ, Jakubowski JA, Deykin D et al. Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time and thromboxane A2 levels in bleeding-time blood. Am J Med 1986 81 : 400 4.
74. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trial of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002 324 : 71 86.
75. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 296 : 313 16.
76. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation and low-dose aspirin in the prevention of ischaemic heart disease in men at increased risk. Lancet 1998 351 : 233 41.
77. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 351 : 1755 62.
78. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001 357 : 89 95.
79. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002 136 : 157 60.
80. D'Agostino RB Sr., Grundy S, Sullivan LM, Wilson P CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001 286 : 180 7.
81. Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 : 1837 47.
82. Lauer MS. Aspirin for primary prevention for coronary events. N Engl J Med 2002 346 : 1468 74.
83. Prodanovich S, Ma F, Taylor JR et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005 52 : 262 7.